Shares

3 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2020

Feb 16, 2021

SELL
$4.92 - $30.67 $7.18 Million - $44.8 Million
-1,459,411 Closed
0 $0
Q3 2020

Nov 16, 2020

BUY
$21.66 - $38.86 $4.49 Million - $8.05 Million
207,226 Added 16.55%
1,459,411 $35.1 Million
Q2 2020

Aug 14, 2020

BUY
$25.47 - $39.69 $31.9 Million - $49.7 Million
1,252,185 New
1,252,185 $48.6 Million

Others Institutions Holding APRE

About Aprea Therapeutics, Inc.


  • Ticker APRE
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Description
  • Aprea Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel cancer therapeutics that target DNA damage response pathways. Its lead product candidate is ATRN-119, an oral ATR inhibitor that is in phase 1/2a clinical trial to treat patients with advanced solid tumors. The company's products...
More about APRE
Track This Portfolio

Track Consonance Capital Management LP Portfolio

Follow Consonance Capital Management LP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Consonance Capital Management LP, based on Form 13F filings with the SEC.

News

Stay updated on Consonance Capital Management LP with notifications on news.